Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 951 - 1,000 out of 9,677

Document Document Title
WO/2016/130691A1
Disclosed herein is a method for treating heart failure in a subject in need thereof. The method includes administering a therapeutically effective amount of nicotinamide riboside to the subject. The heart failure may be associated with ...  
WO/2016/126734A1
Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including t...  
WO/2016/120403A1
The present invention relates to a compound of the general formula (1). wherein the pyranose ring is a-D-galactopyranose, A is selected from The compound of formula (1) is suitable for use in a method for treating a disorder relating to ...  
WO/2016/123397A2
The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs may show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tau...  
WO/2016/120305A1
A compound of formula (I) Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of sai...  
WO/2016/112746A1
Disclosed in the present invention is a method for preparing ribofuranose phosphate derivatives, and the preparation steps thereof comprises: coupling starting materials of isopropyl L-alanine hydrochloride, phenol dichlorophosphate and ...  
WO/2016/113335A1
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal...  
WO/2016/110761A1
An efficient and simple process is provided for producing 1-β-D-arabinofuranosylcytosine or cytarabine wherein cytidine hydrochloride is converted to the corresponding 2,2'- anhydro-1-β-D-arabinofuranosylcytosine hydrochloride by react...  
WO/2016/107289A1
The present invention relates to a method for preparing Sofosbuvir crystal form-6. The method is simple in operation, stable in process condition, good in reproducibility, high in yield rate and high in purity, viscous gel-type products ...  
WO/2016/105449A1
This disclosure provides compounds and compositions for use as analgesics and for the treatment of one or more conditions selected from: pain; psychic pain; psychological pain; psychiatric pain; depression; allodynia; fibromyalgia; fibro...  
WO/2016/101782A1
An oxidized β-nicotinamide adenine dinucleotide phosphate and a purification method therefor, specifically comprising the following steps: a. using membrane concentration equipment to perform microfiltration and then nanofiltration on a...  
WO/2016/106050A1
This disclosure relates to N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment and prophylaxis of viral infections.  
WO/2016/101412A1
Disclosed are a crystallization water-free calcium dibutyryladenosine cyclophosphate crystal form, and a preparation method and a use thereof. In an X-ray powder diffraction pattern using Cu-Kα as a source of radiation, the crystallizat...  
WO/2016/100569A1
Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus infection with one or more nucleosides, nucleotides and nucl...  
WO/2016/097173A1
A process for preparing a crystalline form of sofosbuvir having an X-ray powder diffraction pattern comprising no reflection at 2-theta angles in the range of from 2.0 to 7.8°, wherein polyethylene glycol is used as additive for solvent...  
WO/2016/100441A1
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.  
WO/2016/098028A1
The disclosure relates to nucleic acids that contain modifications at the 5'-end, 3'-end or 5'-end and 3'-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved exp...  
WO/2016/100893A1
Methods and compositions for activating TORC1 aggregate formation in a fungi or a parasite, wherein TORC1 aggregate formation inhibits growth of the fungi or parasite. TORC1 aggregate formation may be activated using small molecules or o...  
WO/2016/100864A1
The present invention provides a method of determining whether cytosine residues present at a predetermined positions within a singl strand of a double stranded DNA of known sequence are methylated as well as compounds for carrying out t...  
WO/2016/094677A2
The invention features a mononucleotide comprising a nucleobase bonded to a sugar having a 3'-carbon and a 5'-carbon, where the 5'-carbon is bonded to a phosphorus (V) atom of a phosphate group through an oxygen atom, the phosphorus (V) ...  
WO/2016/091119A1
Disclosed is a method for purifying oxidized β-nicotinamide adenine dinucleotide, comprising the steps: using a filter membrane to perform microfiltration and nanofiltration on a reaction liquid obtained from an enzyme catalysis reactio...  
WO/2016/091698A1
The present invention relates to compounds of formula (I), wherein R1, R2and R3are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds ...  
WO/2016/091236A1
The present invention provides 6-aryl-9-glycosidpurines of general formula I and pharmaceutically acceptable salts thereof with alkali metals, ammonia, amines, or addition salts with acids, wherein Gly represents β-D-arabinofuranosyl or...  
WO/2016/091235A1
The present invention provides 6-aryl-9-glycosidpurines of general formula I and pharmaceutically acceptable salts thereof with alkali metals, ammonia, amines, or addition salts with acids, wherein Gly represents β-D-arabinofuranosyl or...  
WO/2016/091121A1
Disclosed is a method for purifying reduced β-nicotinamide adenine dinucleotide, comprising the steps: performing microfiltration and then nanofiltration on a reaction liquid obtained from an enzyme catalysis reaction, and collecting th...  
WO/2016/086860A1
Disclosed is a purification method for β-nicotinamide mononucleotide, comprising the following steps: a. using membrane concentration equipment to perform microfiltration and then nanofiltration on a pre-treated β-nicotinamide mononucl...  
WO/2016/090005A1
The present invention is directed to selective adenosine A1 agonist compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, reduce or prevent age-related macular degeneration.  
WO/2016/083830A1
The present invention relates to chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and pharmaceutical compositi...  
WO/2016/078582A1
Novel nucleoside phosphoramidate derivatives and applications thereof are disclosed. The derivatives are compounds as represented by formula (I) or pharmaceutically acceptable acidic salts, solvates or hydrates thereof, wherein R1 is C1-...  
WO/2016/078397A1
Disclosed are a new type of cytidine derivative, having the general formula (I), and an application thereof. The new type of cytidine derivative of the present invention has a growth inhibitory effect, confirmed by testing, on transplant...  
WO/2006/102970A9
The present invention refers to a double-stranded siRNA molecule comprising a sense Strand and an antisense Strand which is essentially complementary to the sense Strand, each of the sense and the antisense Strands comprising at least 17...  
WO/2016/078160A1
Provided are a cytidine derivative and an application thereof, having the general formula (I): the cytidine derivative has a growth inhibitory effect, confirmed by testing, on transplanted colon cancer HCT-116 tumors borne by nude mice, ...  
WO/2016/078163A1
The present invention provides the cytidine derivative dimer of general formula (I), and an application thereof. The cytidine derivative dimer has a significant inhibitory effect on human colon cancer HCT-116 tumor cells, and has a stron...  
WO/2016/078399A1
Disclosed are a new type of cytidine derivative dimer, having the general formula (I), and an application thereof. By means of the optimized molecular design of a cytidine compound, the cytidine derivative dimer of the present invention ...  
WO/2016/081871A1
Phosphoramidate esters and related nucleotide analogs useful in polynucleotide sequencing techniques, and synthetic methods for preparing those compounds, are disclosed. These compounds include nucleotide phosphoramidates analogs that ar...  
WO/2016/074531A1
Provided is a method for preparing Sofosbuvir (Sofosbuvir, I) with uridine as a raw material by etherification, oxidation, addition, condensation and other steps, and the preparation method has readily available raw materials, a simple p...  
WO/2016/074596A1
The present invention provides a nucleoside phosphoramidate derivative and an application thereof, which is specifically a compound represented by formula I, or a pharmaceutically acceptable acidic salt, a solvate or a hydrate thereof. R...  
WO/2016/070569A1
Disclosed are four novel sofosbuvir crystals, namely Crystal H1, Crystal H2, Crystal H3 and Crystal H4, and method for preparing the four crystals. The structures and unit cell parameters of the four novel sofosbuvir crystals are determi...  
WO/2016/069975A1
The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya Ebola and West Nile virus), RSV, HEV, and influenza infe...  
WO/2016/068341A1
The present invention addresses the problem of providing: a compound and a pharmaceutical composition that exhibit superior efficacy against tumors, especially tumors that have acquired gemcitabine resistance. The present invention provi...  
WO/2016/066582A1
The present invention relates to method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solva...  
WO/2016/069489A1
Disclosed herein are methods of preparing a nucleoside analog, which are useful treating diseases and/or conditions such as viral infections, and intermediates thereof.  
WO/2016/066283A1
A process comprising (i) providing a mixture comprising a compound of formula (I) or isomers, stereoisomers, diastereomers, enantiomers or salts thereof; (ii)subjecting the mixture provided in (i) to fluorinating conditions in the presen...  
WO/2016/065248A1
Fluorescent nucleotide analogues are provided herein. Also provided herein are methods of using the nucleotide analogues in sequencing-by-synthesis and signal confinement methods.  
WO/2016/064797A1
The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that ...  
WO/2016/063058A1
Disclosed herein is a novel and inventive synthesis of amino-deoxyavermectins, and in particular, the economically significant, anthelminthic macrolide eprinomectin. The synthesis proceeds via reductive amination of an intermediate in wh...  
WO/2016/055493A1
The invention relates to bola-amphiphilic compounds and their uses for biomedical application. The invention particularly relates to the use of bola-amphiphilic compounds for providing low molecular weight gels (LMWG), useful, in particu...  
WO/2016/057828A1
Silylated-pyrimidine prodrugs, compositions that include the silylated-pyrimidine prodrugs, methods for making the silylated-pyrimidine prodrugs and compositions, and methods for treating cancer using the silylated-pyrimidine prodrugs an...  
WO/2016/055769A1
This application relates to a method of separating the phosphate diastereoisomers of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate (NUC-1031) using crystallisation. In particular, crystallisation from isopropyl alcohol provides gemc...  
WO/2016/051396A1
The present invention provides compounds and pharmaceutical compositions adapted to reduce a load of an RNA virus by at least 50%, the virus causing a pathogenic disease in a mammalian subject, the compound adapted to inhibit the formati...  

Matches 951 - 1,000 out of 9,677